Vanguard Capital Management Acquires 5.03% Stake in Intellia Therapeutics Inc

On April 30, 2026, Vanguard Capital Management LLC filed a Schedule 13G with the SEC, disclosing a new 5.03% ownership stake in Intellia Therapeutics Inc (NTLA). As of the event date on March 31, 2026, the investment adviser reported beneficial ownership of 5,945,571 shares of common stock. This position represents a significant increase from a previously reported 0% stake, crossing the 5% regulatory threshold. The filing indicates that Vanguard holds sole dispositive power over all 5,945,571 shares, while maintaining sole voting power over 861,466 shares. The reported holdings include securities managed by various Vanguard affiliates, such as Vanguard Asset Management Limited and Vanguard Global Advisers, LLC. In accordance with Rule 13d-1(b), Vanguard certified that these shares were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. No other single person's interest in the reported securities exceeds 5% of the total outstanding common stock.